Stock CDXC CHROMADEX CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Consensus ChromaDex Corporation

Equities

CDXC

US1710774076

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
3.44 USD +1.47% Intraday chart for ChromaDex Corporation -6.78% +140.56%
04-23 Chromadex Announces Inaugural Major Grocery Debut of Tru Niagen® At Sprouts Farmers Market CI
04-09 Roth MKM Raises Price Target on ChromaDex to $6 From $4.25, Keeps Buy Rating MT

Evolution of the average Target Price on ChromaDex Corporation

Price target over the last 5 years

History of analyst recommendation changes

278c1894b78.imm2S6pK6duLTx3DaPYqm2tjeA6ez4aGR6NPCf-zJco.4h_FPp4txOvHFXGxPJ5-9UZbNV_6gd_jHskWSsmGQv3pBIcy4iONksE4XA~11d46faf251d9016895ca2b06868f148

Analyst Recommendations on ChromaDex Corporation

Roth MKM Raises Price Target on ChromaDex to $6 From $4.25, Keeps Buy Rating MT
HC Wainwright Adjusts Price Target on ChromaDex to $6 From $5, Maintains Buy Rating MT
HC Wainwright Adjusts Price Target on ChromaDex to $5 From $5.50, Keeps Buy Rating MT
B. Riley Trims ChromaDex's Price Target to $2 From $2.10 After Mixed Q4 Metrics, Keeps Neutral Rating MT
HC Wainwright Adjusts Price Target on ChromaDex to $5.50 From $7, Reiterates Buy Rating MT
Oppenheimer Downgrades ChromaDex to Perform From Outperform, Removes $7 Price Target MT
Roth Capital Adjusts ChromaDex Price Target to $4.25 From $5.75, Maintains Buy Rating MT
B. Riley Downgrades ChromaDex to Neutral from Buy, Notes Reduced 2022 Revenue Guidance, Lowers PT to $2.40 from $6 MT
HC Wainwright Adjusts Price Target on ChromaDex to $7 From $8, Reiterates Buy Rating MT
B. Riley Lowers ChromaDex's Price Target to $6 from $8 on Lower Multiple, Keeps Buy Rating MT
HC Wainwright Adjusts ChromaDex's Price Target to $8 From $12, Keeps Buy Rating MT
B. Riley Lowers ChromaDex's Price Target to $8 from $16 After Q4 Sales Miss Estimates, Maintains Buy Rating MT
Roth Capital Starts ChromaDex at Buy With $7 Price Target MT
CHROMADEX : B. Riley Lowers ChromaDex's PT to $16 from $18 After 'Roughly In Line' Q2 Metrics, Keeps Buy Rating MT
CHROMADEX : HC Wainwright Adjusts ChromaDex PT to $11 From $16, Maintains Buy Rating MT
CHROMADEX : HC Wainwright Adjusts Price Target on ChromaDex to $16 From $7, Maintains Buy Rating MT
CHROMADEX : Oppenheimer Adjusts ChromaDex PT to $17 From $9, Maintains Outperform Rating MT
CHROMADEX : B. Riley Raises ChromaDex' Price Target to $18 from $7, Expects Roughly in-Line Q4 2020 Results; Keeps Buy Rating MT
CHROMADEX : B Riley Raises ChromaDex' Price Target to $18 from $7, Cites Favorable Clinical Studies Reflecting Potentially Broad Relevance; Keeps Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.44 USD
Average target price
6.08 USD
Spread / Average Target
+76.74%
High Price Target
7 USD
Spread / Highest target
+103.49%
Low Price Target
5 USD
Spread / Lowest Target
+45.35%

Consensus detail

Consensus revision (last 18 months)

Analysts covering ChromaDex Corporation

Roth MKM
HC Wainwright
B. Riley
Oppenheimer
Roth Capital Partners

Ratings for ChromaDex Corporation

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CDXC Stock
  4. Consensus ChromaDex Corporation